Cargando…

Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma

BACKGROUND: Ovarian carcinoma is highly dependent on the ubiquitin proteasome system (UPS), but its clinical response to treatment with the proteasome inhibitor bortezomib has been disappointing. This has driven exploration of alternate approaches to target the UPS in ovarian cancer. Recently, prote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Rosie T., Yemelyanova, Anna, Xing, Deyin, Anchoori, Ravi K., Hamazaki, Jun, Murata, Shigeo, Seidman, Jeffrey D., Wang, Tian-Li, Roden, Richard B. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547474/ https://www.ncbi.nlm.nih.gov/pubmed/28784174 http://dx.doi.org/10.1186/s13048-017-0347-y

Ejemplares similares

Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors
por: Anchoori, Ravi K., et al.
Publicado: (2021)

Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor
por: Anchoori, Ravi K., et al.
Publicado: (2023)

RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells
por: Soong, Ruey-Shyang, et al.
Publicado: (2016)

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
por: Fejzo, Marlena S., et al.
Publicado: (2013)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Immunohistochemical detection of Human Papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: Potential utility in diagnosis and management
por: Yemelyanova, A, et al.
Publicado: (2012)

Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer
por: Yu, Qing-xin, et al.
Publicado: (2023)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer
por: Nath, Aritro, et al.
Publicado: (2021)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression
por: Kshirsagar, Malti, et al.
Publicado: (2012)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1
por: Santos-Barriopedro, Irene, et al.
Publicado: (2019)

Hepatitis B virus infection disrupts homologous recombination in hepatocellular carcinoma by stabilizing resection inhibitor ADRM1
por: Zeng, Ming, et al.
Publicado: (2023)

Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer
por: Anchoori, Ravi K., et al.
Publicado: (2018)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer
por: Song, Li, et al.
Publicado: (2019)

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
por: Chan, Angela MY, et al.
Publicado: (2020)

Overexpression of CUEDC2 Predicts Poor Prognosis in Ovarian Serous Carcinomas
por: Wang, Aichun, et al.
Publicado: (2015)

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
por: Chowdhury, Shrabanti, et al.
Publicado: (2023)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
por: Song, Yan, et al.
Publicado: (2021)

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis
por: Zanotti, Laura, et al.
Publicado: (2017)

Fallopian tube origin of supposed ovarian high‐grade serous carcinomas
por: Diniz, Patricia Martini, et al.
Publicado: (2011)

No evidence for PALB2 methylation in high-grade serous ovarian cancer
por: Mikeska, Thomas, et al.
Publicado: (2013)

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
por: Tone, Alicia A, et al.
Publicado: (2014)

Dysregulation of X Chromosome Inactivation in High Grade Ovarian Serous Adenocarcinoma
por: Kang, Jun, et al.
Publicado: (2015)

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017)

Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma
por: Serna-Gallegos, Tasha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6brvn32flc9f10djt8ujc1abgi